Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

R. Iacovelli; C. Ciccarese; G. Tortora

doi:10.1016/j.annonc.2021.06.005

Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1192-1193
Number of pages	2
Journal	Annals of Oncology
Volume	32
Issue number	9
DOIs	https://doi.org/10.1016/j.annonc.2021.06.005
Publication status	Published - Sep 2021

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.annonc.2021.06.005

Cite this

@article{705aec381aef4d7085de1df3cfbd7d89,

title = "Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer",

author = "R. Iacovelli and C. Ciccarese and G. Tortora",

note = "Funding Information: RI served as consultant for Astellas, BMS, Ipsen, Janssen, Merk, MSD, Novartis, Pfizer, and Sanofi and received research grant from Pfizer. GT served as consultant for BMS and MSD. CC has declared no conflicts of interests.",

year = "2021",

month = sep,

doi = "10.1016/j.annonc.2021.06.005",

language = "English",

volume = "32",

pages = "1192--1193",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "9",

}

TY - JOUR

T1 - Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

AU - Iacovelli, R.

AU - Ciccarese, C.

AU - Tortora, G.

N1 - Funding Information: RI served as consultant for Astellas, BMS, Ipsen, Janssen, Merk, MSD, Novartis, Pfizer, and Sanofi and received research grant from Pfizer. GT served as consultant for BMS and MSD. CC has declared no conflicts of interests.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85111019223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111019223&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.06.005

DO - 10.1016/j.annonc.2021.06.005

M3 - Letter

C2 - 34139270

AN - SCOPUS:85111019223

VL - 32

SP - 1192

EP - 1193

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -

Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this